Product image of Migard (Frovatriptan) supplied by GNH India

Migard

Active Ingredient:
Frovatriptan
Origin:
EU

Migard (Frovatriptan)

Frovatriptan, the active ingredient in Migard, is a selective serotonin 5‑HT1B/1D receptor agonist presented as a tablet for oral use. It is indicated for the acute treatment of migraine attacks in adults, providing relief from headache and associated symptoms.

GNH India supplies Migard as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company follows stringent quality standards and provides regulatory documentation to support import and distribution across global markets. Clients benefit from reliable logistics, batch traceability, and responsive technical support throughout the supply chain.

Manufacturer / TM Owner

Menarini International Operations Luxembourg S.A.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Frovatriptan is used in the acute treatment of migraine and related headache disorders.
  • Migraine (with or without aura): provides rapid relief of headache pain, accompanying nausea, photophobia and phonophobia, typically within two hours of administration.
  • Menstrual migraine: reduces the frequency and severity of attacks linked to the menstrual cycle, offering a convenient option for women with predictable hormonal triggers.

How It Works

  • Frovatriptan acts as an agonist at the 5‑HT1B and 5‑HT1D serotonin receptors located on intracranial blood vessels and trigeminal nerve endings. Activation of 5‑HT1B receptors induces cranial vasoconstriction, while stimulation of 5‑HT1D receptors inhibits the release of pro‑inflammatory neuropeptides, thereby interrupting the pain signaling cascade responsible for migraine attacks. The combined vascular and neuronal effects restore normal blood flow and diminish neurogenic inflammation, leading to symptom relief.

Side Effects

Frovatriptan may cause a range of adverse reactions, which are generally categorized by frequency and severity.

Common Side Effects

  • Chest discomfort
  • Tingling or numbness
  • Dizziness
  • Nausea
  • Dry mouth
  • Fatigue

Serious or Rare Side Effects

  • Coronary vasospasm
  • Severe hypertension
  • Serotonin syndrome
  • Allergic reactions (rash, swelling, anaphylaxis)
  • Cardiac arrhythmia
  • Ischemic events (stroke, myocardial infarction)

Precautions & Warnings

  • When prescribing frovatriptan, clinicians should observe several precautionary measures to minimise risk.
  • Assess cardiovascular risk: evaluate history of coronary artery disease, hypertension or cerebrovascular disorders before use.
  • Avoid concomitant ergotamine: combined vasoconstrictive effects may precipitate severe vascular events.
  • Monitor serotonin syndrome: do not co‑administer with other serotonergic agents such as SSRIs, SNRIs or MAO inhibitors.
  • Use caution in older adults: patients over 65 may experience heightened sensitivity to side effects.
  • Store at ambient temperature: keep tablets in the original packaging, protect from moisture and store below 25 °C.

Avoid Interactions

Frovatriptan interacts with several medicines; understanding the level of interaction guides safe co‑administration.

Major Interactions (Avoid)

  • Ergotamine derivatives: additive vasoconstriction can cause serious cardiovascular events.
  • Monoamine oxidase inhibitors (MAOIs): increase risk of serotonin syndrome when combined.

Moderate Interactions (Monitor Closely)

  • SSRIs and SNRIs: may elevate serotonin levels; monitor for signs of serotonin syndrome.
  • CYP1A2 inhibitors (e.g., fluvoxamine, ciprofloxacin): raise frovatriptan plasma concentrations, possibly enhancing side effects.
  • Antihypertensive agents: concurrent use may augment blood pressure‑lowering effects.

Frequently Asked Questions

Migard contains frovatriptan, which is prescribed for the acute treatment of migraine attacks in adults. It helps relieve headache pain as well as associated symptoms such as nausea, photophobia and phonophobia when taken at the onset of an attack.

Frovatriptan works by binding to 5‑HT1B and 5‑HT1D serotonin receptors on cranial blood vessels and trigeminal nerve endings. This causes vasoconstriction of dilated intracranial vessels and blocks the release of inflammatory neuropeptides, interrupting the migraine pain pathway.

The dose of Migard is determined by the prescribing healthcare professional based on the patient’s clinical condition and response. Physicians typically select a single oral tablet dose for an individual migraine attack, and may repeat dosing only if advised.

Safety data for frovatriptan in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by a qualified prescriber.

To order Migard, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Migard (frovatriptan) has a relatively long half‑life compared with many other triptans, which can provide sustained migraine relief and a lower risk of headache recurrence. Its efficacy and safety profile are comparable, but individual response and tolerability may vary.

Migard tablets should be stored at ambient temperature, preferably below 25 °C. Keep them in the original blister pack, protect from moisture and direct sunlight, and keep out of reach of children.

Migard is taken orally as a tablet. The tablet should be swallowed whole with a glass of water, preferably as soon as migraine symptoms begin. It is not intended for use as a preventive medication.

Serious risks associated with Migard include coronary vasospasm, severe hypertension, serotonin syndrome, allergic reactions such as anaphylaxis, cardiac arrhythmias, and ischemic events like stroke or myocardial infarction. Patients should seek immediate medical attention if any of these occur.

Migard should be avoided in individuals with known hypersensitivity to frovatriptan, a history of uncontrolled hypertension, coronary artery disease, cerebrovascular disorders, peripheral vascular disease, or in patients currently taking MAO inhibitors or other serotonergic drugs without medical supervision.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Frovatriptan

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT